MedTrace Logo

Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide

NCT00803920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2015-12-03

No results posted yet for this study

Summary

The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.

Conditions

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • HealthPartners Institute

    lead OTHER

Principal Investigators

  • Richard M Bergenstal, MD · Park Nicollet Institute dba International Diabetes Center

  • Elinor S Strock, APRN, BC · Park Nicollet Institute dba International Diabetes Center

  • Roger S Mazze, PhD · Park Nicollet Institute dba International Diabetes Center

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00803920 on ClinicalTrials.gov